Mapi Pharma Research site 11 — Cullman, Alabama

Mapi Pharma Research site 11 is a clinical research site located in Cullman, Alabama, United States 35058.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Mapi Pharma Research site 11 has participated in 1 clinical trials.

Therapeutic areas: Multiple Sclerosis, Relapsing-Remitting.

Sponsors: Mapi Pharma Ltd..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Cullman

Browse all research sites in Alabama · View every site in Cullman

• Cullman Clinical Trials
• Research Site
• North Central Neurology Associates PC
• North Central Neurology Associates
• Novartis Investigative Site
• North Central Neurology Associates, P.C.
• Alkermes Investigational Site
• Cullman Research Center
• Adamas Clinical Site
• Cullman Clinical Research, Inc
• AllerVie Clinical Research- Cullman
• Cullman Regional

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Mapi Pharma Research site 11?

Mapi Pharma Research site 11 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Mapi Pharma Research site 11 conducted?

Mapi Pharma Research site 11 has 1 clinical trials on record. Their work covers Multiple Sclerosis, Relapsing-Remitting.

Is Mapi Pharma Research site 11 accredited by Crixeo Clinical Trials?

Mapi Pharma Research site 11 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Mapi Pharma Research site 11?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.